Travere Therapeutics Reports First Quarter 2026 Financial Results
Travere Therapeutics reported first quarter 2026 U.S. net product sales of $124.5 million, driven by an 88% year-over-year increase in FILSPARI sales to $105.2 million. On a non-GAAP basis, the company achieved net income of $4.1 million, or $0.05 per share, compared to a net loss of $16.9 million in the prior year, while maintaining a strong cash position of $264.7 million. The FDA approved FILSPARI for FSGS on April 13, 2026, expanding the total addressable patient population in the U.S.
Key figures
- Revenue
- $124.5 million
- Drug Name
- FILSPARI (sparsentan)
- Phase Of Trial
- Phase 3
- Non gaap eps
- $0.05
- Cash position
- $264.7 million
- Filspari sales
- $105.2 million
- Filspari sales growth
- 88%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.